The effect of the SGLT2 inhibitor on the primary outcome was consistent across all subgroups, indicating that SGLT2 inhibitors were associated with a lower risk of the composite of HF hospitalization or death compared to DPP4 inhibitors, regardless of age, gender, comorbidities, prior history of atherosclerotic CV disease or HF, and the use of beta blocker or renin-angiotension system blocker (all p for interaction>0.05, Fig 3). Here, SLC5A2 is linked to hydrops fetalis.